Ladarixin - Dompe Farmaceutici
Alternative Names: DF-2156A; DF-2156Y; LDX - Dompe Farmaceutici; MeraxinLatest Information Update: 18 Mar 2024
At a glance
- Originator Dompe Farmaceutici
- Class Antihyperglycaemics; Small molecules; Sulfonamides
- Mechanism of Action Interleukin 8A receptor antagonists; Interleukin 8B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Type 1 diabetes mellitus
- Phase II Insulin resistance
- Discontinued Bullous pemphigoid; Malignant melanoma; Spinal cord injuries
Most Recent Events
- 08 Mar 2024 Dompe Farmaceutici terminates a phase II trial in Insulin resistance in Italy (PO, Capsule) (EudraCT2020-003296-18)
- 28 Nov 2023 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus(In volunteers) in Switzerland (PO, Capsule)
- 07 Nov 2023 Dompe Farmaceutici terminates a phase-II clinical trials in Type 1 diabetes mellitus (Adjunctive treatment) in the Italy (PO) due to low recruitment rate (NCT05368402) (EudraCT2022-000743-68)